$UFPT earnings report

UFP Technologies Announces Strong Q3 Results. AlphAI read Ufp Technologies's third quarter ended September 30, 2026 filing as strong. 2 quarters are on record below.

third quarter ended September 30, 2026

AlphAI · Earnings readUFPT · third quarter ended September 30, 2026 · ended September 30, 2026

UFP Technologies Announces Strong Q3 Results

✓Strong quarter

Third-quarter sales increased 11.6%, gross margin increased to 29.4%, GAAP net income increased 25.8%, and adjusted operating income increased 14.5%.

Revenue
$172M
11.6% y/y
Gross margin · GAAP
29.4%
EPS · non-GAAP
$2.88

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three months ended September 30, 2026GAAP$172.4M–11.6%
Net sales, nine months ended September 30, 2026GAAP$500.6M–10.3%
Cost of sales, three months ended September 30, 2026GAAP121.7M––
Cost of sales, nine months ended September 30, 2026GAAP354.6M––
Gross profit, three months ended September 30, 2026GAAP50.76M––
Gross profit, nine months ended September 30, 2026GAAP146.0M––
Gross margin, three months ended September 30, 2026GAAP29.4%––
Gross margin, nine months ended September 30, 2026GAAP29.2%––
Selling, general & administrative expenses, three months ended September 30, 2026GAAP$23.2M–21.4%
Selling, general & administrative expenses, nine months ended September 30, 2026GAAP$66.9M–18.5%
SG&A as a percentage of sales, three months ended September 30, 2026GAAP13.4%––
SG&A as a percentage of sales, nine months ended September 30, 2026GAAP13.4%––
Adjusted SG&A, three months ended September 30, 2026non-GAAP$20.65M––
Adjusted SG&A, nine months ended September 30, 2026non-GAAP$59.47M––
Adjusted SG&A as a percentage of sales, three months ended September 30, 2026non-GAAP12.0%––
Adjusted SG&A as a percentage of sales, nine months ended September 30, 2026non-GAAP11.9%––
Acquisition costs, three months ended September 30, 2026GAAP12K––
Acquisition costs, nine months ended September 30, 2026GAAP84K––
Change in fair value of contingent consideration, three months ended September 30, 2026GAAP—––
Change in fair value of contingent consideration, nine months ended September 30, 2026GAAP—––
Gain on disposal of property, plant & equipment, three months ended September 30, 2026GAAP−9K––
Gain on disposal of property, plant & equipment, nine months ended September 30, 2026GAAP−41K––
Operating income, three months ended September 30, 2026GAAP$27.6M–18.1%
Operating income, nine months ended September 30, 2026GAAP$79.1M–11.6%
Adjusted operating income, three months ended September 30, 2026non-GAAP$30.1M–14.5%
Adjusted operating income, nine months ended September 30, 2026non-GAAP$86.6M–9.0%
Interest expense, net, three months ended September 30, 2026GAAP1.49M––
Interest expense, net, nine months ended September 30, 2026GAAP4.94M––
Other income, three months ended September 30, 2026GAAP−6K––
Other income, nine months ended September 30, 2026GAAP−24K––
Income before income tax expense, three months ended September 30, 2026GAAP26.12M––
Income before income tax expense, nine months ended September 30, 2026GAAP74.16M––
Income tax expense, three months ended September 30, 2026GAAP5.50M––
Income tax expense, nine months ended September 30, 2026GAAP15.19M––
Net income, three months ended September 30, 2026GAAP$20.6M–25.8%
Net income, nine months ended September 30, 2026GAAP$59M–16.2%
Adjusted net income, three months ended September 30, 2026non-GAAP$22.5M–21.1%
Adjusted net income, nine months ended September 30, 2026non-GAAP$64.5M–13.0%
Net income per diluted share, three months ended September 30, 2026GAAP$2.64––
Net income per diluted share, nine months ended September 30, 2026GAAP$7.56––
Adjusted net income per diluted share outstanding, three months ended September 30, 2026non-GAAP$2.88––
Adjusted net income per diluted share outstanding, nine months ended September 30, 2026non-GAAP$8.28––
Weighted average diluted common shares outstanding, three months ended September 30, 2026GAAP7,806––
Weighted average diluted common shares outstanding, nine months ended September 30, 2026GAAP7,795––
Organic sales, three months ended September 30, 2026non-GAAP$171.7M–11.1%
Organic sales, nine months ended September 30, 2026non-GAAP$490.0M–7.9%
Net sales from acquired operations, three months ended September 30, 2026non-GAAP−725K––
Net sales from acquired operations, nine months ended September 30, 2026non-GAAP−10.64M––
EBITDA, three months ended September 30, 2026non-GAAP$32.64M––
EBITDA, nine months ended September 30, 2026non-GAAP$93.98M––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$35.4M–15.3%
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$102.8M–10.7%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

What drove it

  • Third-quarter organic sales growth was 11.1%.
  • MedTech sales grew 12.5% in the third quarter, reflecting broad-based demand across the portfolio.
  • Gross margin increased to 29.4% in the third quarter from 27.7% in the same quarter of 2025.
  • Management cited scaling new programs in the Dominican Republic, margin improvements in legacy UFP operations, and investments that broadened capabilities.
  • Management stated that its 2025 investment in TPI exceeded expectations and provides an initial position in injection molding.
  • Management cited significant year-over-year progress at AJR in both the U.S. and the Dominican Republic.

Concerns

  • SG&A increased 21.4% to $23.2 million in the third quarter, and SG&A as a percentage of sales increased to 13.4% from 12.3%.
  • Adjusted SG&A as a percentage of sales increased to 12.0% in the third quarter from 10.7%.
  • Management stated that scheduled program transfers to the Dominican Republic and margin improvement remain behind plan.
  • The filing identifies customer concentration, new product and program launches, program-transfer execution, supply-chain and labor-force disruption, indebtedness and financing-covenant compliance as risks.

What to watch

  • Execution of scheduled program transfers to the Dominican Republic and the pace of margin improvement.
  • Performance of the DAS Medical capacity investment intended to support double-digit growth.
  • Progress on acquisition opportunities, integration of recent investments, and the planned expansion of the credit facility.
  • Customer demand and the performance of the Company’s two largest customers under supply agreements.

Balance sheet and cash flow

  • Cash and cash equivalents were $20,625 (in thousands) as of September 30, 2026, compared with $20,301 (in thousands) as of December 31, 2025.
  • Receivables, net were $97,154 (in thousands) as of September 30, 2026, compared with $82,914 (in thousands) as of December 31, 2025.
  • Inventories were $98,148 (in thousands) as of September 30, 2026, compared with $86,856 (in thousands) as of December 31, 2025.
  • Current portion of long-term debt was $12,500 (in thousands) as of September 30, 2026 and December 31, 2025.
  • Long-term debt, excluding current installments, was $83,500 (in thousands) as of September 30, 2026, compared with $122,955 (in thousands) as of December 31, 2025.
  • Total assets were $682,635 (in thousands) as of September 30, 2026, compared with $655,077 (in thousands) as of December 31, 2025.
  • Total liabilities were $196,920 (in thousands) as of September 30, 2026, compared with $231,200 (in thousands) as of December 31, 2025.
  • Total equity was $485,715 (in thousands) as of September 30, 2026, compared with $423,877 (in thousands) as of December 31, 2025.

Analysis

UFP Technologies reported broad third-quarter growth. Net sales increased 11.6% to $172.4 million, including 11.1% organic sales growth. Management attributed MedTech sales growth of 12.5% to broad-based demand across its portfolio. Through September, sales increased 10.3% to $500.6 million and organic growth was 7.9%.

Profitability improved despite higher overhead. Third-quarter gross margin increased to 29.4% from 27.7%, while GAAP operating income increased 18.1% to $27.6 million and adjusted operating income increased 14.5% to $30.1 million. GAAP net income increased 25.8% to $20.6 million, and GAAP diluted EPS was $2.64 compared with $2.11 in the same quarter of 2025. Adjusted diluted EPS was $2.88 compared with $2.39.

The principal cost offset was SG&A. Third-quarter SG&A increased 21.4% to $23.2 million, and the ratio to sales increased to 13.4% from 12.3%. Adjusted SG&A as a percentage of sales rose to 12.0% from 10.7%. Management cited scaling programs in the Dominican Republic, margin improvements in legacy operations, the TPI investment, and progress at AJR as operational developments, while also stating that Dominican Republic program transfers and margin improvement remain behind plan.

The balance sheet showed cash and cash equivalents of $20,625 (in thousands) and long-term debt, excluding current installments, of $83,500 (in thousands) at September 30, 2026. Management stated that it is working to expand its credit facility to support investment in larger businesses and noted progress on several acquisition opportunities. The release provided no quantitative financial outlook, so the next areas for attention are Dominican Republic transfer execution, DAS Medical capacity investment, acquisition activity, and credit-facility expansion.

Management, verbatim

Our third quarter and year-to-date results reflect continued solid execution across the UFP platform and progress toward our long-term growth strategy.

Mitch Rock, President and Chief Executive Officer

In the third quarter, sales grew 11.6%, including 11.1% organic growth, gross margins increased to 29.4%, and adjusted operating income grew 14.5%. MedTech sales grew 12.5%, reflecting broad-based demand across our portfolio.

Mitch Rock, President and Chief Executive Officer

However, scheduled program transfers to the Dominican Republic and margin improvement remain behind plan.

Mitch Rock, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Quantitative forward guidance for revenue, gross margin, operating expenses, tax rate, earnings, EBITDA, or other financial metrics was not provided.
  • Prior-release outlook was not provided, so comparison of actual results with prior guidance is unavailable.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Share repurchases and dividends were not reported.
  • Segment revenue was not reported.
  • Sequential, prior-quarter comparisons were not reported.
  • GAAP and adjusted EPS year-over-year percentage changes were not reported.
  • A tax rate was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of 2026

AlphAI · Earnings readUFPT · second quarter of 2026 · ended June 30, 2026

UFP Technologies Announces Record Q2 Results

✓Solid quarter

Record quarterly sales, net income and EPS were accompanied by double-digit sales, operating-income and adjusted EBITDA growth, while higher SG&A and Dominican Republic investments created mix and margin pressure within U.S. operations.

Revenue
$174M
15.1% y/y
Gross margin · GAAP
29.3%
EPS · non-GAAP
$2.92

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$174M–15.1%
Organic sales growthnon-GAAP12.4%––
Cost of salesGAAP$123.0M––
Gross profitGAAP$50.92M––
Gross marginGAAP29.3%––
Selling, general & administrative expensesGAAP$22.8M–21.8%
SG&A as a percentage of salesGAAP13.1%––
Adjusted SG&A as a percentage of salesnon-GAAP11.7%––
Acquisition costsGAAP72K––
Change in fair value of contingent considerationGAAP—––
Gain on disposal of property, plant & equipmentGAAP−6K––
Operating incomeGAAP$28.1M–15.5%
Adjusted operating incomenon-GAAP$30.6M–12.3%
Interest expense, netGAAP1.71M––
Other (income) expenseGAAP−40K––
Income before income tax expenseGAAP26.43M––
Income tax expenseGAAP5.58M––
Net incomeGAAP$20.9M–21.4%
Adjusted net incomenon-GAAP$22.7M–17.2%
Net income per shareGAAP$2.69––
Net income per diluted shareGAAP$2.68––
Adjusted diluted EPSnon-GAAP$2.92––
Weighted average common shares outstandingGAAP7.74M––
Weighted average diluted common shares outstandingGAAP7.79M––
Adjusted EBITDAnon-GAAP$36.4M–14.3%
Six-month net salesGAAP$328.2M–9.6%
Six-month organic sales growthnon-GAAP6.8%––
Six-month gross profitGAAP95.28M––
Six-month gross marginGAAP29.0%––
Six-month selling, general & administrative expensesGAAP$43.8M–17.0%
Six-month SG&A as a percentage of salesGAAP13.3%––
Six-month adjusted SG&A as a percentage of salesnon-GAAP11.8%––
Six-month operating incomeGAAP$51.5M–8.5%
Six-month adjusted operating incomenon-GAAP$56.5M–6.4%
Six-month net incomeGAAP$38.3M–11.6%
Six-month adjusted net incomenon-GAAP$42.1M–8.9%
Six-month net income per shareGAAP$4.96––
Six-month net income per diluted shareGAAP$4.92––
Six-month adjusted EPSnon-GAAP$5.39––
Six-month adjusted EBITDAnon-GAAP$67.3M–8.5%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

What drove it

  • Top five customers grew 14.7% during the quarter.
  • The balance of the MedTech business grew 19.7% during the quarter.
  • Non-medical business was flat during the quarter.
  • Management attributed results to contributions across the UFP platform and the strength and diversity of its MedTech business.
  • The company continues to invest in Dominican Republic operations to support customer-driven growth initiatives, expand capacity and enhance its cost structure over time.

Concerns

  • SG&A increased 21.8% to $22.8 million, faster than 15.1% sales growth.
  • GAAP SG&A as a percentage of sales increased to 13.1% from 12.4%, while adjusted SG&A as a percentage of sales increased to 11.7% from 10.8%.
  • Management said full realization of benefits from Dominican Republic investments is taking longer than anticipated.
  • Management said Dominican Republic investments are creating near-term mix and margin pressure within U.S. operations.
  • Non-medical business was flat.

What to watch

  • Progress in realizing operational and cost-structure benefits from Dominican Republic investments.
  • Whether management can reduce near-term mix and margin pressure within U.S. operations.
  • Growth from existing customers, new program launches and the four large programs cited in the forward-looking statements.
  • Sales trends among the top five customers, the remaining MedTech business and non-medical business.
  • Execution of disciplined acquisitions and continued leadership-team expansion.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 9,045 (in thousands) at June 30, 2026, compared with $ 20,301 (in thousands) at December 31, 2025.
  • Receivables, net were 113,247 (in thousands) at June 30, 2026, compared with 82,914 (in thousands) at December 31, 2025.
  • Inventories were 100,090 (in thousands) at June 30, 2026, compared with 86,856 (in thousands) at December 31, 2025.
  • Net property, plant, and equipment were 76,916 (in thousands) at June 30, 2026, compared with 79,109 (in thousands) at December 31, 2025.
  • Current installments, net of long-term debt were 12,500 (in thousands) at June 30, 2026 and 12,500 (in thousands) at December 31, 2025.
  • Long-term debt, excluding current installments, was 104,805 (in thousands) at June 30, 2026, compared with 122,955 (in thousands) at December 31, 2025.
  • Total assets were $ 681,909 (in thousands) at June 30, 2026, compared with $ 655,077 (in thousands) at December 31, 2025.
  • Total liabilities were 219,484 (in thousands) at June 30, 2026, compared with 231,200 (in thousands) at December 31, 2025.
  • Total equity was 462,425 (in thousands) at June 30, 2026, compared with 423,877 (in thousands) at December 31, 2025.

Analysis

UFP Technologies reported record quarterly net sales, net income and EPS for the second quarter ended June 30, 2026. Net sales rose 15.1% to $174.0 million, with 12.4% organic sales growth. GAAP operating income increased 15.5% to $28.1 million, net income increased 21.4% to $20.9 million, and adjusted EBITDA increased 14.3% to $36.4 million. For the six-month period, sales increased 9.6% to $328.2 million and adjusted EBITDA increased 8.5% to $67.3 million.

Demand was concentrated in the medical platform. The top five customers grew 14.7%, while the balance of the MedTech business grew 19.7%; non-medical business was flat. Management cited broad contributions across the platform and the strength and diversity of the MedTech business. It also identified opportunities in existing-customer growth, new program launches and four large programs referenced in its forward-looking statements.

Profitability improved at the gross-profit level, with second-quarter gross margin increasing to 29.3% from 28.8%, and six-month gross margin increasing to 29.0% from 28.6%. Expense leverage was less favorable: quarterly SG&A rose 21.8% to $22.8 million and reached 13.1% of sales, compared with 12.4% a year earlier. Adjusted SG&A as a percentage of sales rose to 11.7% from 10.8%. Management attributed near-term mix and margin pressure within U.S. operations to investments in the Dominican Republic and said the full realization of associated benefits is taking longer than anticipated.

The balance sheet showed $ 9,045 (in thousands) of cash and cash equivalents at June 30, 2026, against long-term debt, excluding current installments, of 104,805 (in thousands). Receivables and inventories were 113,247 (in thousands) and 100,090 (in thousands), respectively. The release did not report operating cash flow, free cash flow, repurchases or dividends.

Management did not provide quantitative forward guidance. Its stated priorities are to support customer-driven growth initiatives, expand Dominican Republic capacity, enhance cost structure, pursue disciplined acquisitions, and add organizational capacity through leadership investments. The key operating issue is whether the company can convert those investments into the anticipated operational benefits while sustaining MedTech-led growth and containing U.S. mix and margin pressure.

Management, verbatim

Our second quarter and first-half results reflect solid execution across the platform and continued progress toward our long-term growth strategy.

Mitch Rock, President and Chief Executive Officer

During the quarter, our top five customers grew 14.7%, the balance of our MedTech business grew 19.7%, and our non-medical business was flat.

Mitch Rock, President and Chief Executive Officer

Looking ahead, we continue to see meaningful opportunities to grow with existing customers, support new program launches, pursue disciplined acquisitions, and invest in our people and capabilities.

Mitch Rock, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Quantitative forward revenue guidance
  • Quantitative forward gross-margin guidance
  • Quantitative forward operating-expense guidance
  • Quantitative forward tax-rate guidance
  • Prior outlook for comparison with actual results
  • Prior-quarter comparisons for reported metrics
  • Reportable-segment revenue
  • Operating cash flow
  • Free cash flow
  • Share repurchases
  • Dividends
  • Cash-flow statement
  • Adjusted EPS prior-year figure for the six-month period
  • Adjusted net income prior-year unit for the six-month period beyond the printed value of $38.6

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about UFPT earnings dates

When is Ufp Technologies's next earnings date?
AlphAI has no date for UFPT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.